Verismo's SynKIR-110 Beats Single-Chain CAR T in Preclinical Study
Philadelphia – November 03, 2026 -- Verismo Therapeutics' SynKIR-110 achieved the fastest tumor control among three CAR T designs in preclinical mesothelioma models while producing roughly 10-fold less IFNγ and 30-fold less TNFα and IL-2 than a CD28-based single-chain CAR T.
The company will present the data at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix (Abstract 253). The study compared SynKIR-110 with CD28- and 4-1BB-based single-chain CAR T cells in mesothelioma xenograft models.
SynKIR-110 shows lower exhaustion markers than both single-chain comparators
Tumor-infiltrating SynKIR-110 CD8 T cells expressed fewer of the exhaustion markers TIM3, LAG3 and PD1 than cells from either single-chain design. In vitro data also showed reductions in T cell exhaustion, off-target proliferation and toxicity.